<table border="0" cellpadding="0" cellspacing="0" width="103%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Clarithromycin Susceptibility Test Results and Clinical/Bacteriological Outcomes<sup>a</sup>
</caption>
<tbody>
<tr>
<td>
<content stylecode="bold">Clarithromycin </content>
<content stylecode="bold">Pretreatment Results</content>
<br/>
</td>
<td>Clarithromycin Post-treatment Results</td>
</tr>
<tr>
<td></td>
<td>
<content stylecode="bold">
<content stylecode="italics">H. pylori </content>
</content>
<content stylecode="bold">negative - eradicated</content>
<br/>
</td>
<td>
<content stylecode="bold">
<content stylecode="italics">H. pylori </content>
</content>
<content stylecode="bold">positive - not eradicated </content>
<content stylecode="bold">
<br/>Post-treatment susceptibility results</content>
<br/>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td>
<content stylecode="bold">S</content>
<content stylecode="bold">
<sup>b</sup>
</content>
<br/>
</td>
<td>
<content stylecode="bold">I</content>
<content stylecode="bold">
<sup>b</sup>
</content>
<br/>
</td>
<td>
<content stylecode="bold">R</content>
<content stylecode="bold">
<sup>b</sup>
</content>
<br/>
</td>
<td>
<content stylecode="bold">No MIC</content>
<br/>
</td>
</tr>
<tr>
<td>
<content stylecode="bold"> Omeprazole 40 mg q.d./clarithromycin 500 mg t.i.d. for 14 days followed by omeprazole 20 mg q.d. for another 14 days (M93-067, M93-100)</content>
<br/>
</td>
</tr>
<tr>
<td> Susceptible<sup>b</sup>
<br/>
</td>
<td>108<br/>
</td>
<td>72<br/>
</td>
<td>1<br/>
</td>
<td></td>
<td>26<br/>
</td>
<td>9<br/>
</td>
</tr>
<tr>
<td> Intermediate<sup>b</sup>
<br/>
</td>
<td> 1<br/>
</td>
<td></td>
<td></td>
<td></td>
<td>1<br/>
</td>
<td></td>
</tr>
<tr>
<td> Resistant<sup>b</sup>
<br/>
</td>
<td> 4<br/>
</td>
<td></td>
<td></td>
<td></td>
<td>4<br/>
</td>
<td></td>
</tr>
<tr>
<td>
<content stylecode="bold"> Ranitidine bismuth citrate 400 mg b.i.d./clarithromycin 500 mg t.i.d. for 14 days followed by ranitidine bismuth citrate 400 mg b.i.d. for another 14 days (H2BA3001)</content>
<br/>
</td>
</tr>
<tr>
<td> Susceptible<sup>b</sup>
<br/>
</td>
<td>124<br/>
</td>
<td>98<br/>
</td>
<td>4<br/>
</td>
<td></td>
<td>14<br/>
</td>
<td>8<br/>
</td>
</tr>
<tr>
<td> Intermediate<sup>b</sup>
<br/>
</td>
<td> 3<br/>
</td>
<td>2<br/>
</td>
<td></td>
<td></td>
<td></td>
<td>1<br/>
</td>
</tr>
<tr>
<td> Resistant<sup>b</sup>
<br/>
</td>
<td>17<br/>
</td>
<td>1<br/>
</td>
<td></td>
<td></td>
<td>15<br/>
</td>
<td>1<br/>
</td>
</tr>
<tr>
<td>
<content stylecode="bold"> Ranitidine bismuth citrate 400 mg b.i.d./clarithromycin 500 mg b.i.d. for 14 days followed by ranitidine bismuth citrate 400 mg b.i.d. for another 14 days (H2BA3001)</content>
<br/>
</td>
</tr>
<tr>
<td> Susceptible<sup>b</sup>
<br/>
</td>
<td>125<br/>
</td>
<td>106<br/>
</td>
<td>1<br/>
</td>
<td>1<br/>
</td>
<td>12<br/>
</td>
<td>5<br/>
</td>
</tr>
<tr>
<td> Intermediate<sup>b</sup>
<br/>
</td>
<td>2<br/>
</td>
<td>2<br/>
</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td> Resistant<sup>b</sup>
<br/>
</td>
<td>20<br/>
</td>
<td>1<br/>
</td>
<td></td>
<td></td>
<td>19<br/>
</td>
<td></td>
</tr>
<tr>
<td>
<content stylecode="bold"> Omeprazole 20 mg b.i.d./clarithromycin 500 mg b.i.d./amoxicillin 1 g b.i.d. for 10 days (126, 127, M96-446)</content>
<br/>
</td>
</tr>
<tr>
<td> Susceptible<sup>b</sup>
<br/>
</td>
<td>171<br/>
</td>
<td>153<br/>
</td>
<td>7<br/>
</td>
<td></td>
<td>3<br/>
</td>
<td>8<br/>
</td>
</tr>
<tr>
<td> Intermediate<sup>b</sup>
<br/>
</td>
<td> <br/>
</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td> Resistant<sup>b</sup>
<br/>
</td>
<td>14<br/>
</td>
<td> 4<br/>
</td>
<td>1<br/>
</td>
<td></td>
<td>6<br/>
</td>
<td>3<br/>
</td>
</tr>
<tr>
<td>
<content stylecode="bold"> Lansoprazole 30 mg b.i.d./clarithromycin 500 mg b.i.d./amoxicillin 1 g b.i.d. for 14 days (M95-399, M93-131, M95-392)</content>
<br/>
</td>
</tr>
<tr>
<td> Susceptible<sup>b</sup>
<br/>
</td>
<td>112<br/>
</td>
<td>105<br/>
</td>
<td></td>
<td></td>
<td></td>
<td>7<br/>
</td>
</tr>
<tr>
<td> Intermediate<sup>b</sup>
<br/>
</td>
<td> 3<br/>
</td>
<td>3<br/>
</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td> Resistant<sup>b</sup>
<br/>
</td>
<td>17<br/>
</td>
<td>6<br/>
</td>
<td></td>
<td></td>
<td>7<br/>
</td>
<td>4<br/>
</td>
</tr>
<tr>
<td>
<content stylecode="bold"> Lansoprazole 30 mg b.i.d./clarithromycin 500 mg b.i.d./amoxicillin 1 g b.i.d. for 10 days (M95-399)</content>
<br/>
</td>
</tr>
<tr>
<td> Susceptible<sup>b</sup>
<br/>
</td>
<td>42<br/>
</td>
<td>40<br/>
</td>
<td>1<br/>
</td>
<td></td>
<td>1<br/>
</td>
<td></td>
</tr>
<tr>
<td> Intermediate<sup>b</sup>
<br/>
</td>
<td> <br/>
</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td> Resistant<sup>b</sup>
<br/>
</td>
<td>4<br/>
</td>
<td>1<br/>
</td>
<td></td>
<td></td>
<td>3<br/>
</td>
<td></td>
</tr>
<tr>
<td>
<sup>a</sup>  Includes only patients with pretreatment clarithromycin susceptibility tests<br/>
<sup>b</sup> Breakpoints for antimicrobial susceptibility testing at the time of studies were: Susceptible (S) MIC &lt; 0.25 mcg/mL, Intermediate (I) MIC 0.5 to 1 mcg/mL, Resistant (R) MIC &gt; 2 mcg/mL. For current antimicrobial susceptibility testing guidelines see reference 4. For current susceptibility test interpretive criteria, see Susceptibility Test for <content stylecode="italics">Helicobacter pylori </content>below.</td>
</tr>
</tbody>
</table>